Tel: 514–461–1300

Our team
  • Director of the Montreal Heart Institute Research Center

    Jean-Claude Tardif, MD is professor of medicine at the Montreal Heart Institute, where he also serves as a cardiologist and Director of the Research Center. Dr. Tardif graduated with a medical degree, from the University of Montreal in 1987 and completed his fellowship in cardiology in 1992. He then completed a research fellowship at the New England Medical Center, Tufts University in 1994. Returning to Montreal, he took up a position as cardiologist at the Heart Institute that same year, where he also holds the Canada Research Chair in translational and personalized medicine. Dr. Tardif also occupies the University of Montreal endowed research chair in atherosclerosis. Dr. Tardif has authored and co-authored more than 600 articles and abstracts in peer-reviewed publications including The New England Journal of Medicine, the Journal of the American Medical Association, the Lancet, Circulation, and the Journal of the American College of Cardiology. In addition, he has written more than 25 book chapters. He is the principal investigator and Steering Committee chair or member of several large international cardiovascular clinical trials.

  • Director, Montreal Health Innovations Coordinating Center (MHICC)

    Dr. Andreas Orfanos received his FFPM from the Royal College of Physicians of the United Kingdom and his MBBCh and MBA from the University of the Witwatersrand, South Africa.
    Dr. Orfanos has over 25 years of extensive international experience in strategy development, executive and operational management roles in major healthcare sectors, with a particular focus on global pharmaceuticals and biotechnology. Prior to joining the MHICC, Dr. Orfanos was Vice President at Thrasos Therapeutics. He also established ORFANOS Global Healthcare Consulting Inc., which focused on creating value for organizations through strategy development and the advancement of medical products and technologies. Dr. Orfanos was formerly Executive Vice President, Strategic Planning and Scientific Affairs at Neurochem. He also served at Picchio Pharma, Novartis Pharmaceuticals, Sandoz and Lifecare. He has held various lead roles in strategy development, business development, leadership of specialty business units, and in drug development and clinical management. He has been instrumental in several leading studies in the fields of transplantation, oncology, renal disease and cardiac surgery.

  • Medical Director, Clinical Research Network

    Dr. Simon Kouz is the Medical Director, Clinical Research Network at the Montreal Health Innovations Coordinating Centre, Chief Cardiologist and Department Head for Specialized Medicine for the Centre de Santé et des Services Sociaux du Nord de Lanaudière (CSSSSNL) and Director of the Research Centre in Cardiology at Joliette. Dr. Kouz graduated with his medical degree in 1979 and completed his training in Cardiology in Paris and Montreal. He is past Associate Dean, Faculty of Medicine of the University of Laval for Joliette. He is Fellow of the American College of Cardiology, Royal College of Physicians and Surgeons of Canada and the European Society of Cardiology. Dr. Kouz was the co-founder and is Executive Committee member of AMI-Quebec since 2003 and is Executive Member of the Counsel Canadian Cardiovascular Society (CCS). He is past President of the Council of Physicians, Dentists and Pharmacists of the CSSSSNL and was co-founder and still an ongoing member of the Community of Cardiologist Committee of the CCS.
    Dr. Kouz has been a collaborator of several large international cardiovascular Steering Committees and numerous Clinical Event Adjudication Committees not to mention his participation on various advisory boards in the Pharmaceutical Industry. He has been a member of the Canadian Cardiovascular Group for the recommendation for Heart Failure for the last 8 years and is presently on the secondary panel for the recommendation on Atrial Fibrillation.
    Dr Kouz is or has been the principal investigator of over 100 large international multicentre clinical trials. He has authored over 120 publications in journals and was co-author for the «Heart and Hypertension» chapter in the Canadian Hypertension Education Program in 2013. He has contributed as expert Cardiologist in over 100 conferences and has given a multitude of conferences in the different areas in Cardiology and Cardiovascular Research at the CSSSSNL. Dr. Kouz is member of the scientific committee for myocardial infarction with the Institut National d'Excellence en Santé et en Services Sociaux (INESSS).

  • Sr. Strategic Adviser

    A graduate of Michigan State University College of Veterinary Medicine, Dr. Heinonen has an active interest in the evaluation of potential cardiovascular biomarkers and their appropriate application in clinical trials. She received training in molecular biology at Merck Research Laboratories, and was a member of the Pfizer Global Research and Development team where she made significant contributions to the clinical development of Lipitor. Including her current responsibilities as Sr.Strategic Adviserb at the MHICC, Dr. Heinonen has accumulated over 19 total years of research, with 17 years dedicated to clinical research. Dr. Heinonen has authored over 50 publications and managed over 30 clinical trials, many of which have focused on critical markers of disease and imaging technologies. Dr. Heinonen has worked as a consultant to government institutions, pharmaceutical companies, and diagnostic companies. In 2003, Dr. Heinonen began organizing the annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium and in 2006 co-founded the International Partnership for Critical Markers of Disease. Dr. Heinonen is the Executive Director of the Canadian Atheroscleroses Imaging Network.

  • Lead, Biostatistics

    Dr. Guertin holds a PhD degree in biostatistics from University of Montreal. For more than 10 years, she has been involved in clinical trials as the head of the Biostatistics department of the MHICC. Between 2005 and 2008, Dr Guertin served as a reviewer on the Randomized Clinical Trial panel of the Canadian Institutes of Health Research (CIHR). She has participated as co-author in numerous peer-reviewed articles (reporting results of clinical trials) published in some of the most reputable scientific journals.

  • Head QA

    Konstantina Panaritis holds a B.Sc. degree in biology from Concordia University and has over 16 years of experience in quality assurance within the pharmaceutical, biopharmaceutical and biotechnology sectors. Prior to joining the MHICC, Ms. Panaritis was a quality consultant in several industries including medical devices, natural health products, pharmaceuticals, and cosmetics. Her expertise includes Quality Management System implementation in regulated environments, internal and external auditing, and an extensive knowledge of European, American and Canadian Regulations and Standards.